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Abstract
Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States of cancers that 
affect both men and women. Despite strong evidence that screening for CRC reduces incidence and mortality, CRC 
screening prevalence is below the national target. This report describes current CRC screening prevalence by age, various 
demographic factors, and state.
Methods: Data from the 2018 Behavioral Risk Factor Surveillance System survey were analyzed to estimate the percentages 
of adults aged 50–75 years who reported CRC screening consistent with the United States Preventive Services Task Force 
recommendation.
Results: In 2018, 68.8% of adults were up to date with CRC screening. The percentage up to date was 79.2% among 
respondents aged 65–75 years and 63.3% among those aged 50–64 years. CRC screening prevalence was lowest among 
persons aged 50–54 years (50.0%) and increased with age. Among respondents aged 50–64 years, CRC screening prevalence 
was lowest among persons without health insurance (32.6%) and highest among those with reported annual household 
income of ≥$75,000 (70.8%). Among respondents aged 65–75 years, CRC screening prevalence was lowest among those 
without a regular health care provider (45.6%), and 
highest among those with reported annual household 
income ≥$75,000 (87.1%). Among states, CRC 
screening prevalence was highest in Massachusetts 
(76.5%) and lowest in Wyoming (57.8%).
Discussion: CRC screening prevalence is lower 
among adults aged 50–64 years, although most 
reported having a health care provider and health 
insurance. Concerted efforts are needed to inform 
persons aged <50 years about the benefit of screening 
so that screening can start at age 50 years.
Introduction
Of cancers that affect both men and women, colorectal cancer 
(CRC) is the second leading cause of cancer death in the United 
States. In 2016, 141,270 cases were diagnosed, and 52,286 per-
sons died from the disease (1). The U.S. Preventive Services Task 
Force recommends that adults at average risk (those who do not 
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have a personal or family history of CRC or polyps, do not have 
inflammatory bowel disease, or a history of genetic syndromes 
associated with CRC) aged 50–75 years be screened for CRC 
by any of six available tests: 1) fecal occult blood test (FOBT), 
2) fecal immunochemical test (FIT), 3) multitarget stool DNA 
(FIT-DNA), 4) computed tomographic colonography (CTC), 
5) sigmoidoscopy, or 6) colonoscopy (2). Strong evidence 
exists that screening for CRC reduces incidence and mortality 
(2). Both CRC incidence and mortality have declined steadily 
over the past 30 years; the decline is attributable in part to the 
increasing percentage of adults aged 50–75 years who are up to 
date with CRC screening (i.e., have completed a CRC screen-
ing test within the recommended time interval) (3,4). Despite 
steady gains, the prevalence of CRC screening is lower than the 
stated national Healthy People 2020 target of 70.5%, and not 
all populations have achieved equivalent gains in CRC screening 
(5). This report describes current CRC screening among U.S. 
adults aged 50–75 years, by demographic characteristics and state.
Methods
The Behavioral Risk Factor Surveillance System (BRFSS) is 
an annual, state-based, random-digit–dialed telephone survey 
of the civilian, noninstitutionalized adult population aged 
≥18 years that collects information on health risk behaviors, 
preventive health practices, and health care access in the 
United States. The median response rate for the 2018 BRFSS 
combined landline and cellular phone survey was 49.9% 
(6). All states and the District of Columbia asked BRFSS 
respondents aged ≥50 years a series of questions about their 
CRC screening status.* Among 222,490 respondents aged 
50–75 years, 16,127 (7.2%) declined to answer, had a missing 
answer, or answered “don’t know/not sure” and were excluded 
from the analysis. Screening status (up to date with CRC 
screening†) was analyzed by age groups, various demographic 
characteristics, and state. Data were weighted to the age, sex, 
and racial/ethnic distribution of each state’s adult population 
using intercensal estimates and were age-standardized to the 
2018 BRFSS population. Chi-squared tests were used to evalu-
ate significant (p<0.005) differences in screening compliance by 
* The following questions were asked as part of the Colorectal Cancer Screening 
module: “A blood stool test is a test that may use a special kit at home to 
determine whether the stool contains blood. Have you ever had this test using 
a home kit?,” “How long has it been since you had your last blood stool test 
using a home kit?,” “Sigmoidoscopy and colonoscopy are exams in which a 
tube is inserted in the rectum to view the colon for signs of cancer or other 
health problems. Have you ever had either of these exams?,” “For a 
sigmoidoscopy, a flexible tube is inserted into the rectum to look for problems. 
A colonoscopy is similar, but uses a longer tube, and you are usually given 
medication through a needle in your arm to make you sleepy and told to have 
someone else drive you home after the test. Was your most recent exam a 
sigmoidoscopy or a colonoscopy?,” and “How long has it been since you had 
your last sigmoidoscopy or colonoscopy?.”
† Current U.S. Preventive Services Task Force recommendations for CRC 
screening include more detailed test type information than can be fully assessed 
using the data available in BRFSS. To best match the updated recommendations, 
“up to date” was defined as the percentage of adults aged 50–75 years who 
reported having had a blood stool test (FOBT or FIT) within the past year, a 
sigmoidoscopy within the past 5 years, and/or a colonoscopy within the 
past 10 years.
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age group (50–64 years and 65–75 years). A test for trend was 
used to evaluate a significant (p<0.005) relationship between 
age and up-to-date screening status. SAS-callable SUDAAN 
(version 9.4: RTI International) was used to analyze all data.
Results
In 2018, 68.8% of respondents reported they were 
up to date with CRC screening, including 79.2% of 
respondents aged 65–75 years and 63.3% of respondents 
aged 50–64 years (Table 1). Among all demographic groups 
studied, a significantly higher percentage of respondents 
aged 65–75 years reported being up to date with CRC 
screening than did respondents aged 50–64 years (p<0.005). 
The difference in the percentage of respondents who were 
up to date between those aged 65–75 years and those aged 
50–64 years was largest (23.1 percentage points) among those 
without health insurance and smallest (11.1 percentage points) 
among respondents who identified as non-Hispanic other/
multiracial. The percentage of respondents who were up to 
date was lowest among those aged 50–54 years (50.0%) and 
highest among those aged 70–75 years (81.3%); increasing age 
was significantly associated with an increasing percentage of 
persons who were up to date (p<0.005) (Figure).
Among younger respondents (those aged 50–64 years), 
reported CRC screening prevalence was lowest among those 
without a regular health care provider (32.7%) and those 
without health insurance (32.6%) and highest among those 
reporting an annual household income of ≥$75,000 (70.8%) 
and college graduates (70.7%) (Table 1). In this age group, 
the percentage of respondents who were up to date with CRC 
TABLE 1. Percentage of respondents aged 50–75 years who reported being up to date* with colorectal cancer screening, by age group and 
selected characteristics — Behavioral Risk Factor Surveillance System (BRFSS), United States, 2018†
Characteristic
Age group (yrs)
All (50–75)  
% (95% CI)
50–64  
% (95% CI)
65–75§  
% (95% CI)
Total 68.8 (68.3–69.3) 63.3 (62.7–63.9) 79.2 (78.5–79.8)
Sex
Men 67.0 (66.3–67.7) 61.1 (60.2–62.0) 78.2 (77.1–79.2)
Women 70.5 (69.9–71.2) 65.4 (64.5–66.2) 80.1 (79.2–80.9)
Race/Ethnicity
White, non-Hispanic 71.0 (70.6–71.5) 65.7 (65.1–66.3) 80.7 (80.1–81.2)
Black, non-Hispanic 70.0 (68.5–71.5) 65.1 (63.2–66.9) 79.7 (76.8–82.3)
Asian/Pacific Islander, non-Hispanic 64.8 (60.7–68.7) 59.1 (54.0–64.0) 76.4 (69.8–81.9)
AI/AN, non-Hispanic 62.1 (58.6–65.5) 55.1 (50.5–59.6) 76.6 (71.7–80.8)
Other/Multiracial, non-Hispanic 65.1 (61.9–68.1) 61.3 (57.5–65.0) 72.4 (66.6–77.5)
Hispanic 56.1 (53.8–58.5) 50.6 (47.9–53.3) 68.5 (63.7–72.9)
Education
Less than high school graduate 53.0 (51.2–54.9) 46.8 (44.6–49.0) 65.5 (62.2–68.6)
High school graduate/GED 65.7 (64.8–66.5) 59.8 (58.7–60.9) 76.7 (75.6–77.8)
Some college/technical school 71.4 (70.6–72.2) 66.0 (64.8–67.1) 81.1 (80.0–82.2)
College graduate 75.6 (74.9–76.2) 70.7 (69.8–71.6) 85.0 (84.2–85.8)
Annual household income ($)
<15,000 58.0 (56.3–59.8) 53.4 (51.3–55.4) 66.9 (63.7–70.0)
15,000–34,999 62.2 (61.1–63.2) 54.5 (53.1–56.0) 75.2 (73.9–76.5)
35,000–49,999 67.5 (65.9–69.0) 60.1 (57.9–62.3) 80.3 (78.7–81.8)
50,000–74,999 72.6 (71.4–73.7) 66.2 (64.5–67.8) 83.8 (82.6–85.0)
≥75,000 76.1 (75.4–76.8) 70.8 (69.9–71.8) 87.1 (86.2–88.0)
Residence location
Metropolitan¶ 72.8 (71.6–73.9) 68.1 (66.5–69.7) 80.2 (78.8–81.4)
Nonmetropolitan 69.4 (68.4–70.4) 64.4 (63.0–65.8) 77.6 (76.3–78.7)
Health insurance status
Yes 71.2 (70.8–71.7) 66.7 (66.0–67.3) 79.7 (79.0–80.3)
No 40.1 (37.3–43.0) 32.6 (30.5–34.7) 55.7 (48.7–62.5)
Regular health care provider status
Yes 72.9 (72.4–73.4) 68.1 (67.5–68.8) 81.6 (81.0–82.3)
No 36.1 (34.6–37.7) 32.7 (31.1–34.4) 45.6 (42.2–49.0)
Abbreviations: AI/AN = American Indian/Alaska Native; CI = confidence interval; GED = general educational development certificate.
* Blood stool test within the past 1 year, sigmoidoscopy within the past 5 years, and/or colonoscopy within the past 10 years.
† Data were weighted to the age, sex, and racial/ethnic distribution of each state’s adult population using intercensal estimates and were age-standardized to the 
2018 BRFSS population.
§ All reported data significantly different (p<0.005) by age group (50–64 years compared with 65–75 years).
¶ Metropolitan is defined as in the center city of a metropolitan statistical area (MSA) or outside the center city of an MSA but inside the county containing the center 
city. Nonmetropolitan is defined as inside a suburban county of the MSA, in an MSA that has no center city, or not in an MSA.
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FIGURE. Percentage of respondents aged 50–75 years who reported being up to date* with colorectal cancer screening, by age — Behavioral 
Risk Factor Surveillance System (BRFSS), United States, 2018†,§
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* Blood stool test within the past 1 year, sigmoidoscopy within the past 5 years, and/or colonoscopy within the past 10 years.
† Data were weighted to the age, sex, and racial/ethnic distribution of each state’s adult population using intercensal estimates and age-standardized to the 2018 
BRFSS population.
§ Test for trend is significantly different (p<0.005).
screening was higher among women (65.4%), those with health 
insurance (66.7%), those with a regular health care provider 
(68.1%), and those living in metropolitan areas (68.1%) 
than it was among men (61.1%), those without health insur-
ance (32.6%), those without a regular health care provider 
(32.7%), and those living in non-metropolitan areas (64.4%). 
As education level and annual household income increased, 
the percentage of respondents who were up to date with CRC 
testing also increased.
Among older respondents (aged 65–75 years), reported 
screening prevalence was lowest among those without a regular 
health care provider (45.6%) and highest among those who 
reported annual household income ≥$75,000 (87.1%). Similar 
to respondents aged 50–64 years, the percentage up to date 
with screening was higher among women, those with health 
insurance, those with a health care provider, and those living in 
metropolitan areas and increased with increasing education and 
annual household income levels. Overall, 81% of respondents 
aged 50–64 years and 94% of those aged 65–75 years who had 
never been screened reported having health insurance.
Among states, Massachusetts had the highest percentage of 
all adults aged 50–75 years and those aged 50–64 years who 
were up to date with CRC screening (76.5% and 72.1%, 
respectively), whereas Wyoming had the lowest percentage 
(57.8% and 51.5%, respectively) (Table 2). Among adults 
aged 65–75 years, Rhode Island had the highest percentage 
who were up to date (84.9%) and Wyoming had the lowest 
(68.5%). The percentage of adults aged 50–64 years who were 
up to date was ≥70.5% in four states and <60% in 11 states. 
In contrast, among adults aged 65–75 years the percentage 
who were up to date exceeded 70.5% in 49 states and the 
District of Columbia.
Discussion
An estimated 68.8% of adults aged 50–75 years were up 
to date with CRC screening in 2018; however, screening 
prevalence among adults aged 50–64 years was 15.9 percentage 
points lower than that among persons aged 65–75 years. The 
percentage up to date with CRC screening varied widely across 
subgroups, with a 54.5 percentage-point difference between 
the subgroups with the highest (persons aged 65–75 years with 
reported annual household income ≥$75,000) and the lowest 
(persons aged 50–64 years without health insurance) screening 
prevalence. Up to date CRC screening status increased with 
increasing age, suggesting that many eligible adults are not 
receiving important screening that can prevent or detect CRC 
early, when treatment is more effective.
CRC screening has increased steadily among adults over the 
past twenty years, but screening prevalence has been consis-
tently higher among those aged 65–75 years than among those 
aged 50–64 years (7). Visits to a primary care provider have 
been associated with participation in CRC screening (8–10). 
In one study, among Medicaid enrollees who had reached age 
50 years within the study time frame, 75% had at least one 
primary care visit within 1 year, but only 17% were screened 
for CRC during that year. The percentage who initiated screen-
ing increased as the number of primary care visits within the 
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TABLE 2. Percentage of respondents aged 50–75 years who reported being up to date* with colorectal cancer screening, by age group and by 
state — Behavioral Risk Factor Surveillance System (BRFSS), United States, 2018†
State
Age group (yrs)
Total (50–75)  
% (95% CI)
50–64  
% (95% CI)
65–75  
% (95% CI)
United States 68.8 (68.3–69.3) 63.3 (62.7–63.9) 79.2 (78.5–79.8)
Alabama 69.5 (67.5–71.5) 64.0 (61.2–66.7) 79.3 (76.4–81.9)
Alaska 60.2 (56.6–63.7) 53.3 (48.6–58.0) 73.1 (68.1–77.6)
Arizona 65.2 (62.7–67.7) 59.6 (56.2–62.9) 76.4 (73.4–79.2)
Arkansas 65.5 (62.9–67.9) 58.8 (55.3–62.1) 77.7 (74.8–80.4)
California 70.9 (69.0–72.7) 64.8 (62.4–67.1) 82.4 (79.5–84.9)
Colorado 68.3 (66.6–70.0) 63.3 (61.1–65.6) 77.3 (75.0–79.5)
Connecticut 74.3 (72.8–75.8) 71.2 (69.2–73.1) 80.6 (78.3–82.7)
Delaware 72.2 (70.0–74.4) 67.5 (64.5–70.4) 80.5 (77.4–83.3)
District of Columbia 72.4 (70.0–74.7) 68.7 (65.4–71.8) 79.9 (76.6–82.8)
Florida 69.0 (66.8–71.2) 61.6 (58.5–64.6) 82.9 (80.2–85.3)
Georgia 68.1 (66.3–69.8) 61.7 (59.3–64.0) 80.8 (78.3–83.0)
Hawaii 74.1 (72.1–76.0) 70.2 (67.5–72.7) 81.0 (78.1–83.6)
Idaho 66.1 (63.0–69.0) 60.3 (56.0–64.3) 75.8 (72.2–79.2)
Illinois 66.7 (64.4–69.0) 62.6 (59.6–65.5) 74.8 (71.2–78.0)
Indiana 67.4 (65.5–69.2) 62.2 (59.7–64.5) 77.3 (74.8–79.7)
Iowa 70.9 (69.4–72.4) 66.5 (64.5–68.5) 78.2 (76.0–80.3)
Kansas 66.8 (65.2–68.3) 61.6 (59.5–63.6) 76.1 (74.0–78.1)
Kentucky 69.3 (66.9–71.6) 64.0 (60.8–67.0) 78.6 (75.2–81.7)
Louisiana 69.0 (66.4–71.5) 64.4 (61.0–67.6) 77.3 (73.3–80.9)
Maine 74.7 (73.1–76.3) 70.4 (68.0–72.6) 81.9 (79.9–83.8)
Maryland 72.1 (70.7–73.4) 67.7 (65.9–69.5) 81.3 (79.5–83.0)
Massachusetts 76.5 (74.5–78.4) 72.1 (69.5–74.6) 84.6 (81.8–87.0)
Michigan 73.8 (72.2–75.4) 69.3 (67.2–71.4) 81.4 (78.9–83.7)
Minnesota 73.3 (72.1–74.4) 68.8 (67.2–70.3) 81.3 (79.5–83.0)
Mississippi 62.3 (60.0–64.6) 55.2 (52.1–58.1) 75.6 (72.4–78.5)
Missouri 69.4 (67.1–71.6) 63.7 (60.6–66.7) 79.8 (77.0–82.4)
Montana 63.3 (60.8–65.8) 56.3 (52.9–59.6) 74.7 (71.1–78.0)
Nebraska 68.2 (66.6–69.8) 63.1 (60.9–65.3) 76.5 (74.4–78.5)
Nevada 60.4 (56.5–64.3) 53.8 (48.9–58.6) 74.2 (68.4–79.3)
New Hampshire 74.8 (72.8–76.6) 71.1 (68.5–73.7) 80.9 (78.3–83.3)
New Jersey 67.4 (63.3–71.3) 59.6 (54.2–64.8) 82.6 (77.0–87.1)
New Mexico 63.9 (61.6–66.2) 56.9 (53.8–59.8) 76.0 (73.1–78.8)
New York 69.5 (68.1–70.9) 64.9 (63.1–66.7) 78.2 (75.8–80.4)
North Carolina 70.9 (68.3–73.4) 64.9 (61.5–68.2) 81.7 (77.8–85.1)
North Dakota 66.9 (64.7–69.0) 61.7 (58.8–64.6) 76.3 (73.3–79.0)
Ohio 66.7 (65.1–68.4) 61.4 (59.2–63.6) 76.3 (74.2–78.4)
Oklahoma 62.0 (59.7–64.4) 54.9 (51.7–58.0) 75.2 (72.0–78.1)
Oregon 71.4 (69.1–73.6) 66.6 (63.5–69.6) 80.1 (76.8–83.0)
Pennsylvania 71.4 (69.1–73.5) 66.9 (64.1–69.7) 78.6 (75.4–81.5)
Rhode Island 75.7 (73.5–77.7) 71.0 (68.1–73.8) 84.9 (82.1–87.4)
South Carolina 69.6 (68.0–71.2) 63.5 (61.3–65.7) 80.5 (78.5–82.3)
South Dakota 68.1 (65.2–70.8) 63.8 (60.0–67.4) 76.0 (71.8–79.7)
Tennessee 68.3 (65.7–70.7) 61.5 (58.0–64.8) 81.2 (77.9–84.1)
Texas 59.6 (56.2–63.0) 54.0 (50.0–58.0) 71.6 (65.8–76.8)
Utah 69.8 (68.0–71.5) 64.2 (61.8–66.5) 80.1 (77.6–82.3)
Vermont 71.2 (69.1–73.1) 66.6 (64.1–69.1) 77.5 (74.5–80.2)
Virginia 69.3 (67.5–71.1) 63.8 (61.4–66.1) 80.0 (77.5–82.2)
Washington 70.7 (69.1–72.1) 65.7 (63.6–67.7) 79.3 (77.3–81.2)
West Virginia 67.2 (65.1–69.3) 62.2 (59.3–65.0) 76.6 (73.7–79.4)
Wisconsin 74.8 (72.4–77.1) 70.0 (66.9–73.0) 82.9 (79.4–85.9)
Wyoming 57.8 (55.4–60.1) 51.5 (48.3–54.6) 68.5 (65.3–71.7)
Abbreviation: CI = confidence interval.
* Blood stool test within the past 1 year, sigmoidoscopy within the past 5 years, and/or colonoscopy within the past 10 years.
† Data were weighted to the age, sex, and racial/ethnic distribution of each state’s adult population using intercensal estimates and were age-standardized to the 
2018 BRFSS population.
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previous year increased (9). Having a primary care visit at age 
49 years was associated with higher CRC screening initiation 
at age 50 years, but only 69% of patients saw a provider at 
age 49 years (11). Modeling studies have estimated that ini-
tiating screening at age 50 years results in larger decreases in 
population CRC incidence and mortality than when screen-
ing is started at age 55 years, suggesting that delayed or slow 
uptake of CRC screening might diminish the beneficial effect 
of screening on the population (12).
Although lack of health insurance has been strongly associ-
ated with low CRC screening prevalence (7), the majority of 
persons in this study who had never been screened reported 
having health insurance. Other patient barriers to CRC 
screening include lack of a provider recommendation, being 
offered colonoscopy only instead of a choice of tests, lack of 
awareness of the need to be screened, fear, expense, compet-
ing priorities, inability to take time off work if referred for a 
colonoscopy, and the perceived undesirable nature of screening 
tests (e.g., sampling and storing fecal matter for stool tests or 
completing a bowel preparation for colonoscopy) (13–16). 
Other factors positively associated with CRC screening include 
use of other preventive services such as cholesterol testing, 
receiving influenza vaccination, and mammography or cervi-
cal cancer screening. Factors negatively associated with CRC 
screening include provider workload and increasing distance to 
facilities that perform colonoscopy. Patient comorbid disease 
might be positively associated with CRC screening because 
these patients might see their health care provider more fre-
quently, thus increasing the number of opportunities to offer 
screening, or negatively associated as patients with multiple 
comorbid diseases might be sicker and unable to participate 
in screening (10,11,17,18). Less is known about how these 
factors vary and consequently affect CRC screening by age.
There was substantial state variation in the percentage of 
adults aged 50–75 years who reported being up to date with 
CRC screening. Given that adults aged 50–64 years accounted 
for 60%–70% of the population of adults aged 50–75 years 
in each state, in general, states with the highest reported CRC 
screening prevalence for this age group also had the highest 
overall CRC screening prevalence. Variations in the percentage 
of the population without health insurance, who are racial/
ethnic minorities, or who live in rural or frontier areas, as well 
as the availability of providers who perform colonoscopy and 
the number of primary care providers per capita, might also 
contribute to differences in CRC screening by state.
The findings in this report are subject to at least three limita-
tions. First, CRC screening prevalence might be overestimated 
because BRFSS does not specify whether tests were done for 
screening or diagnostic purposes. Second, data are self-reported 
and not validated by medical record review. Third, response 
Summary 
What is already known about this topic?
Screening for colorectal cancer (CRC), the second leading cause 
of cancer death among cancers affecting men and women, 
reduces incidence and mortality. The percentage of persons 
who report being up to date with CRC screening has increased, 
but not equally among all populations.
What is added by this report?
In 2018, 68.8% of adults were up to date with CRC screening 
test use, but screening prevalence was 15.9 percentage points 
lower among those aged 50–64 years than among those aged 
65–75 years.
What are the implications for public health practice?
Specific population-based efforts to increase CRC screening 
are needed so that screening might start at age 50 years and 
continue as recommended through age 75 years for 
maximum benefit. 
rates were low (49.9%), although the BRFSS weighting pro-
cedure accounts for nonresponse, and 7.2% of all respondents 
did not answer all of the questions and were excluded from 
the analysis.
CRC screening is a grade A recommendation from the U.S. 
Preventive Services Task Force, meaning that there is strong 
evidence it effectively decreases CRC incidence and mortality. 
A microsimulation modeling study found that increasing CRC 
screening prevalence to 80% had the potential to decrease 
CRC incidence and mortality by 22% and 33% respectively 
by 2030 (19). This would result in 277,000 new cases averted 
and 203,000 deaths prevented by 2030. These results assume 
that participants start screening at age 50 years and continue 
periodic screening as recommended through age 75 years.
Whereas 68.8% of the U.S. population aged 50–75 years 
reports being up to date with CRC screening, screening 
prevalence is lower among younger adults, especially those 
aged 50–54 years. To achieve further increases in CRC screen-
ing to maximize benefit, specific efforts to increase screen-
ing in persons aged 50–64 years are needed. Partnerships 
between public health and health care systems to implement 
evidence-based interventions such as those described in The 
Community Guide (20) (e.g., provider reminders, patient 
reminders, provider assessment and feedback, and reduction of 
structural barriers) can increase CRC screening even in hard-
to-reach populations, as demonstrated by CDC’s Colorectal 
Cancer Control Program (CRCCP) (https://www.cdc.gov/
cancer/crccp/about.htm). The CRCCP funds states, tribes, 
and universities to partner with primary care clinics to imple-
ment evidence-based interventions to increase CRC screen-
ing. Over 3 years, recipients partnered with approximately 
600 clinics reaching approximately 1 million adults aged 
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50–75 years. Most clinics were Federally Qualified Health 
Centers, which provide health care in underserved areas. 
Implementation of evidence-based interventions resulted 
in an average 10 percentage-point increase in screening 
prevalence in participating clinics. Additional efforts might 
include educating adults about the benefit of screening well 
before age 50 years so that screening can start at age 50 years, 
providing education about insurance coverage for preventive 
services, providing clear communication about test options, 
and conducting research to identify and understand barriers 
and facilitators to CRC screening specific to this younger age 
group to inform effective interventions to increase screening.
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